Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

Journal:
Proceedings of the National Academy of Sciences of the United States of America
Published:
DOI:
10.1073/pnas.2026849118
Affiliations:
3
Authors:
14
Institutions Authors Share
Ludwig Center at Stanford, United States of America (USA)
12.000000
12.000000
0.86
Ben-Gurion University of the Negev (BGU), Israel
1.000000
0.07
Stanford Medicine, United States of America (USA)
1.000000
0.07